Microalbuminuria and hypertension in HIV-infected patients: A preliminary study of telmisartan

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 4, 2012, Pages 491-498

  Ucciferri, C ^a,c   Falasca, K ^c   Mancino, P ^a   Di Iorio, A ^b   Vecchiet, J ^a  

^a Infectious Diseases Clinic   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF MOLISE   (Italy)

Author keywords

Endothelin 1; HIV infection; Kidney disease; Microalbuminuria; Telmisartan; VEGF

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TELMISARTAN; TRIACYLGLYCEROL; VASCULOTROPIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; BIOLOGICAL MARKER;

ADULT; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DIET; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MALE; MICROALBUMINURIA; PROTEIN BLOOD LEVEL; RENAL PROTECTION; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; VIREMIA; ALBUMINURIA; ARTICLE; BLOOD; BLOOD PRESSURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; ITALY; KIDNEY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VIROLOGY;

ADULT; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL MARKERS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; ITALY; KIDNEY; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862706178     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. SMIT C, GESKUS R, WALKER S, SABIN C, COUTINHO R, PORTER K, PRINS M; CASCADE COLLABORATION. Effective therapy has altered the spectrum of causespecific mortality following HIV seroconversion. AIDS 2006; 20: 741-749.
2. TEBAS P. HIV and cardiometabolic abnormalities: New perspectives and treatment update. J Acquir Immune Defic Syndr 2008; 49 (Suppl 2): 77-78.
3. FALASCA K, UCCIFERRI C, MANZOLI L, MANCINO P, PIZZIGALLO E, CONTI P, VECCHIET J. Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. Int J Immunopathol Pharmacol 2007; 20: 519-527.
4. HICKS C, CURRIER J, SAX P, SHERER R, WANKE C. Current management challenges in HIV: Tolerability of antiretrovirals and metabolic complications. AIDS Patient Care STDS 2003; 17: 221-233.
5. FINE DM, PERAZELLA MA, LUCAS GM, ATTA MG. Renal disease in patients with HIV infection: Epidemiology, pathogenesis and management. Drugs 2008; 68: 963-980.
6. SMITH RD, YOKOYAMA H, AVERILL DB, COOKE L, BROSNIHAN KB, SCHIFFRIN EL, FERRARIO CM. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): Rationale and baseline characteristics. Am J Cardiovasc Drugs 2006; 6: 335-342.
7. SCHWARTZ EJ, SZCZECH LA, ROSS MJ, KLOTMAN ME, WINSTON JA, KLOTMAN PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005; 16: 2412-2420.
8. CORESH J, ASTOR BC, MCQUILLAN G, KUSEK J, GREENE T, VAN LENTE F, LEVEY AS. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002; 39: 920-929.
9. SZCZECH LA, GUPTA SK, HABASH R, GUASCH A, KALAYJIAN R, APPEL R, FIELDS TA, SVETKEY LP, FLANAGAN KH, KLOTMAN PE, WINSTON JA. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66: 1145-1152.
10. GARDNER LI, HOLMBERG SD, WILLIAMSON JM, SZCZECH LA, CARPENTER CC, ROMPALO AM, SCHUMAN P, KLEIN RS; HIV EPIDEMIOLOGY RESEARCH STUDY GROUP. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 203-209.
11. SZCZECH LA, HOOVER DR, FELDMAN JG, COHEN MH, GANGE SJ, GOOZÉ L, RUBIN NR, YOUNG MA, CAI X, SHI Q, GAO W, ANASTOS K. ASSOCIATION BEtween re-nal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39: 1199-1206.
12. KLAUSEN K, BORCH-JOHNSEN K, FELDT-RASMUSSEN B, JENSEN G, CLAUSEN P, SCHARLING H, APPLEYARD M, JENSEN JS. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32-35.
13. ROMUNDSTAD S, HOLMEN J, KVENILD K, HALLAN H, ELLEKJAER H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis 2003; 42: 466-473.
14. CHOI AI, LI Y, DEEKS SG, GRUNFELD C, VOLBERDING PA, SHLIPAK MG. Association between kidney function and albuminuria with cardiovascular events in HIVinfected persons. Circulation 2010; 121: 651-658.
15. GEORGE E, LUCAS GM, NADKARNI GN, FINE DM, MOORE R, ATTA MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 2010; 24: 387-394.
16. SZCZECH LA, GRUNFELD C, SCHERZER R, CANCHOLA JA, VAN DER HORST C, SIDNEY S, WOHL D, SHLIPAK MG. Microalbuminuria in HIV infection. AIDS 2007; 21: 1003-1009.
17. VALLE R, HARAGSIM L. Nephrotoxicity as a complication of antiretroviral therapy. Adv Chronic Kidney Dis 2006; 13: 314-319.
18. BRUGGEMAN LA, ROSS MD, TANJI N, CARA A, DIKMAN S, GORDON RE, BURNS GC, D'AGATI VD, WINSTON JA, KLOTMAN ME, KLOTMAN PE. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11: 2079-2087.
19. SZCZECH LA, MENEZES P, BYRD QUINLIVAN E, VAN DER HORST C, BARTLETT JA, SVETKEY LP. Microalbuminuria predicts overt proteinuria among patients with HIV infection. HIV Med 2010; 11: 419-426.
20. YAMAGISHI S, TAKEUCHI M. Telmisartan is a promising cardiometabolic sartan due to its unique PPARgamma-inducing property. Med Hypotheses 2005; 64: 476-478.
21. BALIGA RS, LIU C, HOYT DG, CHAVES AA, BAUER JA. Vascular endothelial toxicity induced by HIV protease inhibitor: Evidence of oxidant-related dysfunction and apoptosis. Cardiovasc Toxicol 2004; 4: 199-206.
22. BAEKKEN M, OS I, SANDVIK L, OEKTEDALEN O. Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol Dial Transplant 2008; 23: 3130-3137.
23. GAZZARUSO C, BRUNO R, GARZANITI A, GIORDANETTI S, FRATINO P, SACCHI P, FILICE G. Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21: 1377-1382.
24. BROWN TT, COLE SR, LI X, KINGSLEY LA, PALELLA FJ, RIDDLER SA, VISSCHER BR, MARGOLICK JB, DOBS AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165: 1179-1184.
25. JUNG O, BICKEL M, DITTING T, RICKERTS V, WELK T, HELM EB, STASZEWSKI S, GEIGER H. Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant 2004; 19: 2250-2258.
26. GUPTA SK, EUSTACE JA, WINSTON JA, BOYDSTUN II, AHUJA TS, RODRIGUEZ RA, TASHIMA KT, ROLAND M, FRANCESCHINI N, PALELLA FJ, LENNOX JL, KLOTMAN PE, NACHMAN SA, HALL SD, SZCZECH LA. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-1585.
27. LAW MG, FRIIS-MØLLER N, EL-SADR WM, WEBER R, REISS P, D'ARMINIO MONFORTE A, THIÉBAUT R, MORFELDT L, DE WIT S, PRADIER C, CALVO G, KIRK O, SABIN CA, PHILLIPS AN, LUNDGREN JD; D:A:D STUDY GROUP. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: Comparison with observed events in the D:A:D Study. HIV Med 2006; 7: 218-230.
28. BAKRIS G, BURGESS E, WEIR M, DAVIDAI G, KOVAL S; AMADEO STUDY INVESTIGATORS. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74: 364-369.
29. TOKUNAGA M, KABASHIMA N, SERINO R, SHIBATA T, MATSUMOTO M, MIYAMOTO T, MIYAZAKI M, FURUNO Y, NAKAMATA J, FUJIMOTO Y, TAKEUCHI M, ABE H, OKAZAKI M, OTSUJI Y, TAMURA M. Renoprotective effects of telmisartan in patients with advanced chronic kidney disease. Clin Nephrol 2010; 73: 139-146.
30. GRUPO DE TRABAJO PARA EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL DE LA SOCIEDAD EUROPEA; SOCIEDAD EUROPEA DE CARDIOLOGÍA, MANCIA G, DE BACKER G, DOMINICZAK A, CIFKOVA R, FAGARD R, GERMANO G, GRASSI G, HEAGERTY AM, KJELDSEN SE, LAURENT S, NARKIEWICZ K, RUILOPE L, RYNKIEWICZ A, SCHMIEDER RE, BOUDIER HA, ZANCHETTI A, VAHANIAN A, CAMM J, DE CATERINA R, DEAN V, DICKSTEIN K, FILIPPATOS G, FUNCK-BRENTANO C, HELLEMANS I, KRISTENSEN SD, MCGREGOR K, SECHTEM U, SILBER S, TENDERA M, WIDIMSKY P, ZAMORANO JL, ERDINE S, KIOWSKI W, ET AL. ESH/ESC 2007 Guidelines for the management of arterial hypertension. Rev Esp Cardiol 2007; 60: 968.e1-94.
31. MANN JF, SCHMIEDER RE, MCQUEEN M, DYAL L, SCHUMACHER H, POGUE J, WANG X, MAGGIONI A, BUDAJ A, CHAITHIRAPHAN S, DICKSTEIN K, KELTAI M, METSÄRINNE K, OTO A, PARKHOMENKO A, PIEGAS LS, SVENDSEN TL, TEO KK, YUSUF S; ONTARGET INVESTIGATORS. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
32. VOGT L, NAVIS G, KÖSTER J, MANOLIS AJ, REID JL, DE ZEEUW D; ANGIOTENSIN II RECEPTOR ANTAGONIST TELMISARTAN MICARDIS IN ISOLATED SYSTOLIC HYPERTENSION (ARAMIS) STUDY GROUP. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: Results of a randomized, double-blind, placebo-controlled trial. J Hypertens 2005; 23: 2055-2061.
33. MORIMOTO S, YANO Y, MAKI K, SAWADA K. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006; 29: 567-572.
34. MAKINO H, HANEDA M, BABAZONO T, MORIYA T, ITO S, IWAMOTO Y, KAWAMORI R, TAKEUCHI M, KATAYAMA S; INNOVATION STUDY GROUP. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577-1578.
35. UCCIFERRI C, MANCINO P, VECCHIET J, FALASCA K. Beneficial effects of telmisartan in an HIV+ diabetic insulin-dependent patient. Int J Immunopathol Pharmacol 2009; 22: 853-857.
36. VECCHIET J, UCCIFERRI C, FALASCA K, MANCINO P, DI IORIO A, DE CATERINA R. Anti-hypertensive and metabolic effects of telmisartan in hypertensive HIVpositive patients. Antivir Ther 2011; 16: 639-645.
37. BENSON SC, PERSHADSINGH HA, HO CI, CHITTIBOYINA A, DESAI P, PRAVENEC M, QI N, WANG J, AVERY MA, KURTZ TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
38. INOUE T, MOROOKA T, MOROE K, IKEDA H, NODE K. Effect of telmisartan on cholesterol levels in patients with hypertension-Saga Telmisartan Aggressive Research (STAR). Horm Metab Res 2007; 39: 372-376.
39. TAKANO H, HASEGAWA H, ZOU Y, KOMURO I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des 2004; 10: 2779-2786.
40. MANCIA G, DE BACKER G, DOMINICZAK A, CIFKOVA R, FAGARD R, GERMANO G, GRASSI G, HEAGERTY AM, KJELDSEN SE, LAURENT S, NARKIEWICZ K, RUILOPE L, RYNKIEWICZ A, SCHMIEDER RE, BOUDIER HA, ZANCHETTI A, VAHANIAN A, CAMM J, DE CATERINA R, DEAN V, DICKSTEIN K, FILIPPATOS G, FUNCK-BRENTANO C, HELLEMANS I, KRISTENSEN SD, MCGREGOR K, SECHTEM U, SILBER S, TENDERA M, WIDIMSKY P, ZAMORANO JL, ERDINE S, ET AL; MANAGEMENT OF ARTERIAL HYPERTENSION OF THE EUROPEAN SOCIETY OF HYPERTENSION; EUROPEAN SOCIETY OF CARDIOLOGY. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
41. CHEN J, MUNTNER P, HAMM LL, FONSECA V, BATUMAN V, WHELTON PK, HE J. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003; 14: 469-477.
42. FALASCA K, UCCIFERRI C, MANCINO P, PIZZIGALLO E, CALZA L, VECCHIET J. Severe HIV-associated hypertriglyceridaemia treated with rosuvastatin plus omega-3 fatty acids. Int J STD AIDS 2009; 20: 580-581.
43. FESSEL WJ, FOLLANSBEE SE, REGO J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: Implications for pathogenesis of fat redistribution. AIDS 2002; 16: 1785-1789.
44. YANAGISAWA M, KURIHARA H, KIMURA S, TOMOBE Y, KOBAYASHI M, MITSUI Y, YAZAKI Y, GOTO K, MASAKI T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
45. IGLARZ M, CLOZEL M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol 2007; 50: 621-628.
46. LERMAN A, ZEIHER AM. Endothelial function: Cardiac events. Circulation 2005; 111: 363-368.
47. LEE CH, OLSON P, EVANS RM. Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003; 144: 2201-2207.
48. SHLIPAK MG, SARNAK MJ, KATZ R, FRIED LF, SELIGER SL, NEWMAN AB, SISCOVICK DS, STEHMAN-BREEN C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060.
49. MUNTNER P, MANN D, WINSTON J, BANSILAL S, FARKOUH ME. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol 2008; 102: 54-57.
50. LEUNG DW, CACHIANES G, KUANG WJ, GOEDDEL DV, FERRARA N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
51. BELGORE FM, BLANN AD, LI-SAW-HEE FL, BEEVERS DG, LIP GY. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 2001; 87: 805-807, A9.
52. HOVIND P, TARNOW L, OESTERGAARD PB, PARVING HH. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl 2000; 75: S56-61.
53. ASSELBERGS FW, DE BOER RA, DIERCKS GF, LANGEVELD B, TIO RA, DE JONG PE, VAN VELDHUISEN DJ, VAN GILST WH. Vascular endothelial growth factor: The link between cardiovascular risk factors and microalbuminuria? Int J Cardiol 2004; 93: 211-215.
54. MAKINO H, HANEDA M, BABAZONO T, MORIYA T, ITO S, IWAMOTO Y, KAWAMORI R, TAKEUCHI M, KATAYAMA S; INNOVATION STUDY GROUP. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: A post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res 2008; 31: 657-664.
55. SANCHEZ RA, MASNATTA LD, PESINEY C, FISCHER P, RAMIREZ AJ. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens 2008; 26: 2393-2398.
56. ASSELBERGS FW, DE BOER RA, DIERCKS GF, LANGEVELD B, TIO RA, DE JONG PE, VAN VELDHUISEN DJ, VAN GILST WH. Vascular endothelial growth factor: The link between cardiovascular risk factors and microalbuminuria? Int J Cardiol 2004; 93: 211-215.
57. MAKINO H, HANEDA M, BABAZONO T, MORIYA T, ITO S, IWAMOTO Y, KAWAMORI R, TAKEUCHI M, KATAYAMA S; INNOVATION STUDY GROUP. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: A post-hoc analysis of the incipient to overt: Angiotensin II blocker, Telmisartan, investigation on Type 2 diabetic nephropathy (INNOVATION) study. Hypertens Res 2008; 31: 657-664.
58. SANCHEZ RA, MASNATTA LD, PESINEY C, FISCHER P, RAMIREZ AJ. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens 2008; 26: 2393-2398.